Q-Med Says $3B Medicis-Valeant Deal Violates Licensing Pact

Law360, New York (November 9, 2012, 5:29 PM EST) -- Q-Med AB launched a suit in New York federal court Wednesday seeking to prevent Medicis Pharmaceutical Corp. from transferring marketing rights for Q-Med's skin care products to rival Valeant Pharmaceuticals International Inc., which has announced plans to buy Medicis for $2.6 billion.

Sweden-based Q-Med claims Medicis is going ahead with the Valeant deal despite being informed that Q-Med won't consent to any deal that transfers Medicis' exclusive North American marketing rights for Q-Med dermal filler products Restylane, Perlane and Sub-Q to Valeant, which directly competes with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.